Aurobindo Pharma Limited has informed the Exchange about Investor Presentation
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 crore (up 5.6% YoY) with EBITDA of ₹1,801 crore (20.3% margin) and net profit of ₹921 crore. Full-year FY26 revenue stood at ₹33,653 crore (6.1% YoY growth). US revenue declined 13% YoY to ₹3,543 crore due to lower transient product sales, but Europe surged 30.2% to ₹2,795 crore and Growth Markets grew 24.7% to ₹980 crore. The company received 9 ANDA approvals and launched 12 products in the US during the quarter. CuraTeQ (biosimilars) secured 3 EMA and 4 UK approvals across 5 products, with an Omalizumab Phase 3 successfully completed. TheraNym expanded its MSD partnership with a greenfield facility (Unit 2) requiring $150-175 million capex. Net cash position post-Khandelwal Labs acquisition stood at ~$317 million.
Aurobindo delivered steady Q4 growth driven by Europe and Growth Markets offsetting US weakness. The expanding biosimilar portfolio and TheraNym MSD partnership expansion signal strong future growth catalysts as the company diversifies into high-value biologics.